Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.45 USD | +7.19% | -4.73% | -39.13% |
May. 09 | Pulse Biosciences, Inc. Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System | CI |
May. 07 | Transcript : Pulse Biosciences, Inc., Q1 2024 Earnings Call, May 07, 2024 |
Financials (USD)
Sales 2022 | 0.7 | Sales 2023 | - | Capitalization | 674M |
---|---|---|---|---|---|
Net income 2022 | -58M | Net income 2023 | -42M | EV / Sales 2022 | 168,485,877 x |
Net Debt 2022 | 14.82M | Net cash position 2023 | 35.22M | EV / Sales 2023 | - |
P/E ratio 2022 |
-1.61
x | P/E ratio 2023 |
-13.9
x | Employees | 56 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 29.62% |
Latest transcript on Pulse Biosciences, Inc.
1 day | +7.19% | ||
1 week | -4.73% | ||
Current month | +1.09% | ||
1 month | +0.54% | ||
3 months | -11.10% | ||
6 months | +44.38% | ||
Current year | -39.13% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Danahy
CEO | Chief Executive Officer | 54 | 22-02-13 |
Chief Tech/Sci/R&D Officer | - | 23-05-02 | |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Duggan
CHM | Chairman | 79 | 17-11-01 |
Director/Board Member | 46 | 17-11-01 | |
Darrin Uecker
CTO | Chief Tech/Sci/R&D Officer | 59 | 15-09-14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.36% | 4 M€ | -5.15% | - | |
0.00% | 0 M€ | +3.63% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 7.45 | +7.19% | 150,500 |
24-05-09 | 6.95 | +0.72% | 217,170 |
24-05-08 | 6.9 | -9.21% | 147,815 |
24-05-07 | 7.6 | -1.68% | 233,503 |
24-05-06 | 7.73 | -1.15% | 194,682 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-39.13% | 411M | |
+11.73% | 226B | |
+9.53% | 188B | |
+14.63% | 137B | |
+27.47% | 108B | |
-0.04% | 63.19B | |
+13.73% | 52.26B | |
+4.86% | 51B | |
+7.72% | 43.89B | |
+7.86% | 38.07B |
- Stock Market
- Equities
- PLSE Stock